# LONZA

Summary updated: 2026-03-20T04:56:53.91345Z
Canonical: https://finbar.com/research/companies/lonza

## Overview

Lonza is a global life sciences company focused primarily on contract development and manufacturing services for the pharmaceutical, biotechnology, and cell-and-gene therapy markets. The company supports customers from pre-clinical development through commercial manufacturing, covering both drug substance and drug product, and its core offerings span biologics, small molecules, and cell & gene technologies; it has also served pharmaceutical and nutraceutical customers through capsules and health ingredients.[1](https://app.finbar.com/go?id=P-b334b95f574540b2a6566e1331280b61)[2](https://app.finbar.com/go?id=P-5a4eb0a6b24c4860a98569ec931e6008)[3](https://app.finbar.com/go?id=P-ec3127010a574c948dd455e625c4bf7e)[4](https://app.finbar.com/go?id=P-3979fa60aca040b4aa116c574440ee58)[5](https://app.finbar.com/go?id=P-6f6fd1dbd9aa4df1a4aa92b984a8d138)[6](https://app.finbar.com/go?id=P-5883408a86904442a9f7ddbe2d29b766)[7](https://app.finbar.com/go?id=P-adf5ec8d8b024ffb87786c3de6fbd3c1) Lonza describes its purpose as turning customers’ breakthrough innovations into viable therapies and manufacturing the medicines of tomorrow, with a vision of being a pioneer and world leader in the CDMO industry.[8](https://app.finbar.com/go?id=P-1dd5971248524475be611380e38f7a22)

The company operates through a global development and manufacturing network of more than 30 sites, with operations including the US, UK, Netherlands, Switzerland, Singapore, China, and Spain, giving it a broad presence across the Americas, EMEA, APAC, and Switzerland.[9](https://app.finbar.com/go?id=P-a4fc12737818404f801e6cf913afc0be)[10](https://app.finbar.com/go?id=P-45ad05e6a6734373a2d6c43dd467ed55)[11](https://app.finbar.com/go?id=P-99dae2a2ef0242f595333d459628a9ee) As a size indicator, Lonza reported 2024 sales of CHF 6,574 million and approximately 18,500 employees on a full-time equivalent basis.[12](https://app.finbar.com/go?id=P-be7f5c5dc9fe4c519c2afcfe456bc948)[13](https://app.finbar.com/go?id=P-fc4da0a2ec7f4288b668c986d4a5a8d1)
[1](https://app.finbar.com/go?id=P-b334b95f574540b2a6566e1331280b61)[2](https://app.finbar.com/go?id=P-5a4eb0a6b24c4860a98569ec931e6008)[3](https://app.finbar.com/go?id=P-ec3127010a574c948dd455e625c4bf7e)[4](https://app.finbar.com/go?id=P-3979fa60aca040b4aa116c574440ee58)[5](https://app.finbar.com/go?id=P-6f6fd1dbd9aa4df1a4aa92b984a8d138)[6](https://app.finbar.com/go?id=P-5883408a86904442a9f7ddbe2d29b766)[7](https://app.finbar.com/go?id=P-adf5ec8d8b024ffb87786c3de6fbd3c1)[8](https://app.finbar.com/go?id=P-1dd5971248524475be611380e38f7a22)[9](https://app.finbar.com/go?id=P-a4fc12737818404f801e6cf913afc0be)[10](https://app.finbar.com/go?id=P-45ad05e6a6734373a2d6c43dd467ed55)[11](https://app.finbar.com/go?id=P-99dae2a2ef0242f595333d459628a9ee)[12](https://app.finbar.com/go?id=P-be7f5c5dc9fe4c519c2afcfe456bc948)[13](https://app.finbar.com/go?id=P-fc4da0a2ec7f4288b668c986d4a5a8d1)

## Products & services

Lonza’s product and service portfolio is centered on outsourced development and manufacturing for pharmaceutical ingredients and finished dosage forms. In small molecules, it offers API development and manufacture, GMP intermediates, micronized APIs, and spray-dried dispersions used to improve bioavailability, plus drug-product services for oral and inhaled formulations in tablet and capsule forms, as well as multiparticulates and injectables; the division is described as an integrated provider spanning drug substance, particle engineering, drug product, and packaging solutions.[14](https://app.finbar.com/go?id=P-aebcca99c2fd44a8bf9d4ef6ee7263c6)[15](https://app.finbar.com/go?id=P-b4f0a5b236e64235a325a23f49a6fcc5)[5](https://app.finbar.com/go?id=P-6f6fd1dbd9aa4df1a4aa92b984a8d138)[16](https://app.finbar.com/go?id=P-bc1383aa0fe4429e87ba033ff85f51dc)[17](https://app.finbar.com/go?id=P-114d5e0763474b23b904c5f55e2db3f2)[18](https://app.finbar.com/go?id=P-3cf8e622ab1c4cc09d933e0a45732dca)[19](https://app.finbar.com/go?id=P-caa1f32a2a5f40e281e7e54a41c49fe1)[20](https://app.finbar.com/go?id=P-d4be33bddf51417cbea7db32b15c1f67)[21](https://app.finbar.com/go?id=P-543d44a90a8745ffb63803c70ad7d0f4) It also offers spray-drying of biologics such as monoclonal antibodies, oligonucleotides and peptides for clinical supply and pulmonary delivery.[22](https://app.finbar.com/go?id=P-349d8f57f36841b792b4e8cb5b721699) In biologics, Lonza provides mammalian manufacturing from clinical to commercial scale, including facilities with 2,000 L, 6,000 L and 20,000 L bioreactors, a Vacaville site with around 330,000 L of bioreactor capacity, and additional Visp capacity with six 20,000 L bioreactors and N-1 perfusion for next-generation monoclonal antibodies.[23](https://app.finbar.com/go?id=P-2d7d98613c9c4dcb97937f2ce1576493)[24](https://app.finbar.com/go?id=P-2da94eea70ba476db728640b8725c9c6)[25](https://app.finbar.com/go?id=P-0f4168c527c149f5b42da1ccab9e6249) Its bioconjugation and ADC offering covers antibodies and proteins combined with linker and payload types including cytotoxic molecules, oligonucleotides, polysaccharides and radiolabeled molecules, and the company says it has produced more than 1,400 cGMP batches for more than 70 programs since 2006.[26](https://app.finbar.com/go?id=P-a31ab4c6ac524a21a0a46105223e2b2e)[27](https://app.finbar.com/go?id=P-93b201a5f970424683184c6a3229a2f2)[28](https://app.finbar.com/go?id=P-df825ea53e094aad80f9eface0b204a4) Drug Product Services add formulation, process design, primary packaging, and fill-finish capabilities for injection and infusion products across intravenous, subcutaneous and intravitreal routes, including standard monoclonal antibodies, bispecifics, fusion proteins, recombinant proteins and ADCs.[29](https://app.finbar.com/go?id=P-ddaae155f9074c8bbf8d5ed7822ccfdb)[30](https://app.finbar.com/go?id=P-e64de2fbe2ee4084b2baeba997b5b8ee)[31](https://app.finbar.com/go?id=P-d194acfc293347e0bccc7d2c0e3a7b99)[32](https://app.finbar.com/go?id=P-da893621dfaf477f8491a57115a0f42a)

In cell and gene technologies, Lonza’s modalities include exosome-based therapies, iPSCs, MSCs, NK and other allogeneic cell therapies, autologous CAR-T, TIL, HSC, TCR and T-reg gene therapies, plus viral vectors including AAVs and LVVs.[33](https://app.finbar.com/go?id=P-bda95475c8a648ecbf93de8b7671c018) Its Cocoon® platform is a functionally closed, automated and scalable autologous cell-manufacturing system intended for decentralized production; Lonza reports more than 150 installed instruments and over 30 customers.[34](https://app.finbar.com/go?id=P-c797dd8bfa43485d9c448f4cbaf7ccad)[35](https://app.finbar.com/go?id=P-85f2c6ebe27a4756b1361b1d123e3cf6) The Xcite® AAV transient transfection platform uses proprietary cell-line and plasmid engineering, and Lonza says its next-generation products include a helper-virus-free stable producer cell-line platform plus medium and enhancer for HEK293 cells.[36](https://app.finbar.com/go?id=P-8acb141ecc88461884952987e2eb9584) In Bioscience, the company sells cell-culture and discovery technologies, cell-culture media, quality-control tests and software for biomanufacturing; named offerings include TheraPEAK® T-VIVO® Cell Culture Medium for clinical-scale expansion of gamma delta T cells, Nucleofector® transfection technology, the MODA-ES® manufacturing execution platform, and microbial manufacturing services in Visp using the XS Technologies® expression system at scales from 70 L to 15,000 L.[37](https://app.finbar.com/go?id=P-05a9cda6bb804e82985f43a32ba4faa9)[38](https://app.finbar.com/go?id=P-9cce667b6b0647ec9bf793959f8969dc)[39](https://app.finbar.com/go?id=P-f0b35cb1e1184af0a385d6938b4d3986)[40](https://app.finbar.com/go?id=P-b144f07b71cc4bdabd2f0057e4264899)[41](https://app.finbar.com/go?id=P-bfa865693eb64f40b03b2a1084c9683c)

Lonza also markets capsule and nutrition products, including gelatin and plant-based Capsugel® capsules with different release profiles and encapsulation technologies, including options designed for vegetarian, vegan, organic and clean-label requirements.[42](https://app.finbar.com/go?id=P-dea544d3f3c44b71bb71038890915c08) Its dosage-form services for nutraceutical customers include end-to-end contract manufacturing, proprietary liquid-sealing technology, and more complex multi-dose and timed-release systems, with additional support in formulation, finished-product co-creation and branding.[43](https://app.finbar.com/go?id=P-b918d1074fda4b34b84942fcf0745486) The health-ingredients portfolio includes UC-II® undenatured type II collagen for joint health and Carnipure® L-carnitine for energy, along with other immune and digestive health ingredients.[44](https://app.finbar.com/go?id=P-70c1b0fa9842473d9b1bcb1513a83f3f) In 2024, third-party sales were led by Biologics at CHF 3,676 million (55.9% of group sales), followed by Capsules & Health Ingredients at CHF 1,054 million (16.0%), Small Molecules at CHF 983 million (15.0%), and Cell & Gene at CHF 689 million (10.5%).[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c)
[14](https://app.finbar.com/go?id=P-aebcca99c2fd44a8bf9d4ef6ee7263c6)[15](https://app.finbar.com/go?id=P-b4f0a5b236e64235a325a23f49a6fcc5)[5](https://app.finbar.com/go?id=P-6f6fd1dbd9aa4df1a4aa92b984a8d138)[16](https://app.finbar.com/go?id=P-bc1383aa0fe4429e87ba033ff85f51dc)[17](https://app.finbar.com/go?id=P-114d5e0763474b23b904c5f55e2db3f2)[18](https://app.finbar.com/go?id=P-3cf8e622ab1c4cc09d933e0a45732dca)[19](https://app.finbar.com/go?id=P-caa1f32a2a5f40e281e7e54a41c49fe1)[20](https://app.finbar.com/go?id=P-d4be33bddf51417cbea7db32b15c1f67)[21](https://app.finbar.com/go?id=P-543d44a90a8745ffb63803c70ad7d0f4)[22](https://app.finbar.com/go?id=P-349d8f57f36841b792b4e8cb5b721699)[23](https://app.finbar.com/go?id=P-2d7d98613c9c4dcb97937f2ce1576493)[24](https://app.finbar.com/go?id=P-2da94eea70ba476db728640b8725c9c6)[25](https://app.finbar.com/go?id=P-0f4168c527c149f5b42da1ccab9e6249)[26](https://app.finbar.com/go?id=P-a31ab4c6ac524a21a0a46105223e2b2e)[27](https://app.finbar.com/go?id=P-93b201a5f970424683184c6a3229a2f2)[28](https://app.finbar.com/go?id=P-df825ea53e094aad80f9eface0b204a4)[29](https://app.finbar.com/go?id=P-ddaae155f9074c8bbf8d5ed7822ccfdb)[30](https://app.finbar.com/go?id=P-e64de2fbe2ee4084b2baeba997b5b8ee)[31](https://app.finbar.com/go?id=P-d194acfc293347e0bccc7d2c0e3a7b99)[32](https://app.finbar.com/go?id=P-da893621dfaf477f8491a57115a0f42a)[33](https://app.finbar.com/go?id=P-bda95475c8a648ecbf93de8b7671c018)[34](https://app.finbar.com/go?id=P-c797dd8bfa43485d9c448f4cbaf7ccad)[35](https://app.finbar.com/go?id=P-85f2c6ebe27a4756b1361b1d123e3cf6)[36](https://app.finbar.com/go?id=P-8acb141ecc88461884952987e2eb9584)[37](https://app.finbar.com/go?id=P-05a9cda6bb804e82985f43a32ba4faa9)[38](https://app.finbar.com/go?id=P-9cce667b6b0647ec9bf793959f8969dc)[39](https://app.finbar.com/go?id=P-f0b35cb1e1184af0a385d6938b4d3986)[40](https://app.finbar.com/go?id=P-b144f07b71cc4bdabd2f0057e4264899)[41](https://app.finbar.com/go?id=P-bfa865693eb64f40b03b2a1084c9683c)[42](https://app.finbar.com/go?id=P-dea544d3f3c44b71bb71038890915c08)[43](https://app.finbar.com/go?id=P-b918d1074fda4b34b84942fcf0745486)[44](https://app.finbar.com/go?id=P-70c1b0fa9842473d9b1bcb1513a83f3f)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c)

## Geographic presence

Lonza is headquartered in Basel, Switzerland, and its geographic footprint is centered on Europe, North America and Asia. The company reports more than 30 global development and manufacturing sites, with major named locations including Basel, Stein and Visp in Switzerland; Portsmouth and Vacaville in the US; Slough and Cambridge in the UK; Oss and Geleen in the Netherlands; Porriño in Spain; Colmar in France; and Tuas in Singapore.[46](https://app.finbar.com/go?id=P-66df0a0a974f4238a4520e8fc8ff6a56)[9](https://app.finbar.com/go?id=P-a4fc12737818404f801e6cf913afc0be)[10](https://app.finbar.com/go?id=P-45ad05e6a6734373a2d6c43dd467ed55)[47](https://app.finbar.com/go?id=P-1c9d6fc417324d46b42e7d9716922f65) Lonza’s official locations directory lists 43 locations worldwide: 20 in Europe, 16 in the Americas and 7 in Asia.[48](https://www.lonza.com/about-us/our-locations)

Lonza discloses external customer revenue by customer destination rather than by manufacturing location. In 2024, Europe was the largest sales region at CHF 3,292 million, or about 49% of revenue, followed by North and Central America at CHF 2,260 million, or about 34%, and Asia at CHF 1,050 million, or about 16%; Latin America, Australia and New Zealand, and other countries were together about 2%.[49](https://app.finbar.com/go?id=P-4ae6ade60bf8405197e319c8a35f369c)[50](https://app.finbar.com/go?id=T-831b8bfd4c2f4934b95f0db502057557) The largest country markets disclosed were the United States at CHF 2,136 million, Switzerland at CHF 1,168 million, and Japan at CHF 544 million; Ireland, Belgium, Denmark and Germany were also individually significant markets.[50](https://app.finbar.com/go?id=T-831b8bfd4c2f4934b95f0db502057557)

Its operating asset base is more concentrated in Europe than its sales mix. Of CHF 11,931 million of non-current assets in 2024, CHF 8,797 million, or about 74%, were in Europe, including CHF 4,686 million in Switzerland, while North and Central America accounted for CHF 2,518 million, or about 21%, and Asia CHF 534 million, or about 4%.[49](https://app.finbar.com/go?id=P-4ae6ade60bf8405197e319c8a35f369c)[50](https://app.finbar.com/go?id=T-831b8bfd4c2f4934b95f0db502057557) Lonza had approximately 18,500 FTE employees in 2024 and reports headcount by Americas, EMEA, APAC and Switzerland, indicating that Switzerland is tracked separately from the broader EMEA region.[13](https://app.finbar.com/go?id=P-fc4da0a2ec7f4288b668c986d4a5a8d1)[51](https://app.finbar.com/go?id=P-48bf834b4b6f42c98ab36aa647984c8f)[11](https://app.finbar.com/go?id=P-99dae2a2ef0242f595333d459628a9ee)
[46](https://app.finbar.com/go?id=P-66df0a0a974f4238a4520e8fc8ff6a56)[9](https://app.finbar.com/go?id=P-a4fc12737818404f801e6cf913afc0be)[10](https://app.finbar.com/go?id=P-45ad05e6a6734373a2d6c43dd467ed55)[47](https://app.finbar.com/go?id=P-1c9d6fc417324d46b42e7d9716922f65)[49](https://app.finbar.com/go?id=P-4ae6ade60bf8405197e319c8a35f369c)[50](https://app.finbar.com/go?id=T-831b8bfd4c2f4934b95f0db502057557)[13](https://app.finbar.com/go?id=P-fc4da0a2ec7f4288b668c986d4a5a8d1)[51](https://app.finbar.com/go?id=P-48bf834b4b6f42c98ab36aa647984c8f)[11](https://app.finbar.com/go?id=P-99dae2a2ef0242f595333d459628a9ee)[48](https://www.lonza.com/about-us/our-locations)

## Business segments

Lonza reports four operating segments/divisions under IFRS 8: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Corporate is disclosed separately and mainly comprises central functions such as finance and accounting, legal, communication, treasury, IT, and human resources rather than a customer-facing business segment.[52](https://app.finbar.com/go?id=P-d44eff9c490e4661b484a5ca2c0f88fe)[53](https://app.finbar.com/go?id=P-9a1ed28a20964acb9de95e76f67e636f)[54](https://app.finbar.com/go?id=P-18cc4f170b7b4138a76a964987cbf37f)

Biologics is Lonza’s largest segment, focused on contract development and manufacturing for biopharmaceuticals across drug substance and drug product, including mammalian and microbial expression systems, bioconjugates, mRNA, related technologies, and drug product services; it accounted for about 57% of 2024 operating-segment third-party sales (CHF 3,676 million of CHF 6,402 million).[55](https://app.finbar.com/go?id=P-0ac689f122aa4b2cb8029e04e122f3f5)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c) Small Molecules provides integrated development and manufacturing for small molecule drug substances and intermediates, with capabilities spanning design, development, manufacturing, particle engineering, and drug product packaging, and contributed about 15% of operating-segment sales (CHF 983 million).[16](https://app.finbar.com/go?id=P-bc1383aa0fe4429e87ba033ff85f51dc)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c) Cell & Gene contributed about 11% (CHF 689 million) and is organized around three business areas—Cell & Gene Technologies, Personalized Medicine, and Bioscience—covering cell and gene therapy manufacturing platforms and services, the Cocoon patient-scale autologous cell therapy platform, and specialty raw materials and enabling technologies; Bioscience is therefore part of Cell & Gene rather than a separate reportable segment.[56](https://app.finbar.com/go?id=P-114828a44837411d8728946e0759a4cb)[57](https://app.finbar.com/go?id=P-468e4cb3967b4fa196b8eaa10e7fe053)[58](https://app.finbar.com/go?id=P-e35357d2ad554497998a8f1360791294)[59](https://app.finbar.com/go?id=P-bf80e7d54e8440bd8e0c3da38b5db0c4)[60](https://app.finbar.com/go?id=P-18a27f20885d44d3b3be6e0e8d44316c)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c) Capsules & Health Ingredients focuses on capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies and represented about 16% of operating-segment sales (CHF 1,054 million).[61](https://app.finbar.com/go?id=P-cef56a8e07d04575b11f1f854b32976d)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c)
[52](https://app.finbar.com/go?id=P-d44eff9c490e4661b484a5ca2c0f88fe)[53](https://app.finbar.com/go?id=P-9a1ed28a20964acb9de95e76f67e636f)[54](https://app.finbar.com/go?id=P-18cc4f170b7b4138a76a964987cbf37f)[55](https://app.finbar.com/go?id=P-0ac689f122aa4b2cb8029e04e122f3f5)[45](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c)[16](https://app.finbar.com/go?id=P-bc1383aa0fe4429e87ba033ff85f51dc)[56](https://app.finbar.com/go?id=P-114828a44837411d8728946e0759a4cb)[57](https://app.finbar.com/go?id=P-468e4cb3967b4fa196b8eaa10e7fe053)[58](https://app.finbar.com/go?id=P-e35357d2ad554497998a8f1360791294)[59](https://app.finbar.com/go?id=P-bf80e7d54e8440bd8e0c3da38b5db0c4)[60](https://app.finbar.com/go?id=P-18a27f20885d44d3b3be6e0e8d44316c)[61](https://app.finbar.com/go?id=P-cef56a8e07d04575b11f1f854b32976d)

## Company history

Lonza was founded in 1897 in the Swiss Alps by Basel banker Alfons Ehinger. Its early development was tied to hydroelectric power from the River Lonza, and by 1927 the company was producing nitric acid for fertilizers; over the following decades, Lonza described its broader evolution as a shift from supplying energy, light and fertilizer toward medical treatments and technologies.[62](https://www.lonza.com/about-us/our-history)[63](https://app.finbar.com/go?id=P-75c44695b6c24a5a91beb3c26eea5b93)[64](https://app.finbar.com/go?id=P-8150cce485c84782ad8d6a799e5865a5)

In the 2010s and 2020s, Lonza reshaped itself around healthcare and life-sciences manufacturing through a series of major portfolio moves. The company acquired Capsugel in 2017 for USD 5.5 billion, expanding its capsule and dosage-form capabilities, then divested Water Care in 2019 and sold its Specialty Ingredients business in 2021, narrowing its focus.[65](https://www.lonza.com/news/2017-07-06-05-00)[66](https://www.lonza.com/news/2019-03-01-06-00)[67](https://www.lonza.com/news/2021-07-02-07-00) In 2023, Lonza acquired Synaffix to strengthen its bioconjugates and antibody-drug conjugate offering, and in 2024 Wolfgang Wienand became CEO after an interim period under Albert M. Baehny, marking another leadership transition in the company’s development.[68](https://www.lonza.com/news/2023-06-01-07-00)[69](https://app.finbar.com/go?id=P-54edf26abc7a4aafb4c6e286b60843e0)[70](https://app.finbar.com/go?id=P-0c136e2126b34597a4e02245b2a9572e)
[63](https://app.finbar.com/go?id=P-75c44695b6c24a5a91beb3c26eea5b93)[64](https://app.finbar.com/go?id=P-8150cce485c84782ad8d6a799e5865a5)[69](https://app.finbar.com/go?id=P-54edf26abc7a4aafb4c6e286b60843e0)[70](https://app.finbar.com/go?id=P-0c136e2126b34597a4e02245b2a9572e)[62](https://www.lonza.com/about-us/our-history)[65](https://www.lonza.com/news/2017-07-06-05-00)[66](https://www.lonza.com/news/2019-03-01-06-00)[67](https://www.lonza.com/news/2021-07-02-07-00)[68](https://www.lonza.com/news/2023-06-01-07-00)

## Sources

1. [LONZA — Full financial report (2024 Y), p11](https://app.finbar.com/go?id=P-b334b95f574540b2a6566e1331280b61)
2. [LONZA — Full financial report (2024 Y), p11](https://app.finbar.com/go?id=P-5a4eb0a6b24c4860a98569ec931e6008)
3. [LONZA — Full financial report (2024 Y), p23](https://app.finbar.com/go?id=P-ec3127010a574c948dd455e625c4bf7e)
4. [LONZA — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-3979fa60aca040b4aa116c574440ee58)
5. [LONZA — Full financial report (2024 Y), p23](https://app.finbar.com/go?id=P-6f6fd1dbd9aa4df1a4aa92b984a8d138)
6. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-5883408a86904442a9f7ddbe2d29b766)
7. [LONZA — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-adf5ec8d8b024ffb87786c3de6fbd3c1)
8. [LONZA — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-1dd5971248524475be611380e38f7a22)
9. [LONZA — Full financial report (2024 Y), p7](https://app.finbar.com/go?id=P-a4fc12737818404f801e6cf913afc0be)
10. [LONZA — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-45ad05e6a6734373a2d6c43dd467ed55)
11. [LONZA — Full financial report (2024 Y), p14](https://app.finbar.com/go?id=P-99dae2a2ef0242f595333d459628a9ee)
12. [LONZA — Full financial report (2024 Y), p7](https://app.finbar.com/go?id=P-be7f5c5dc9fe4c519c2afcfe456bc948)
13. [LONZA — Full financial report (2024 Y), p7](https://app.finbar.com/go?id=P-fc4da0a2ec7f4288b668c986d4a5a8d1)
14. [LONZA — Full financial report (2024 Y), p23](https://app.finbar.com/go?id=P-aebcca99c2fd44a8bf9d4ef6ee7263c6)
15. [LONZA — Full financial report (2024 Y), p23](https://app.finbar.com/go?id=P-b4f0a5b236e64235a325a23f49a6fcc5)
16. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-bc1383aa0fe4429e87ba033ff85f51dc)
17. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-114d5e0763474b23b904c5f55e2db3f2)
18. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-3cf8e622ab1c4cc09d933e0a45732dca)
19. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-caa1f32a2a5f40e281e7e54a41c49fe1)
20. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-d4be33bddf51417cbea7db32b15c1f67)
21. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-543d44a90a8745ffb63803c70ad7d0f4)
22. [LONZA — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-349d8f57f36841b792b4e8cb5b721699)
23. [LONZA — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-2d7d98613c9c4dcb97937f2ce1576493)
24. [LONZA — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-2da94eea70ba476db728640b8725c9c6)
25. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-0f4168c527c149f5b42da1ccab9e6249)
26. [LONZA — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-a31ab4c6ac524a21a0a46105223e2b2e)
27. [LONZA — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-93b201a5f970424683184c6a3229a2f2)
28. [LONZA — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-df825ea53e094aad80f9eface0b204a4)
29. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-ddaae155f9074c8bbf8d5ed7822ccfdb)
30. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-e64de2fbe2ee4084b2baeba997b5b8ee)
31. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-d194acfc293347e0bccc7d2c0e3a7b99)
32. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-da893621dfaf477f8491a57115a0f42a)
33. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-bda95475c8a648ecbf93de8b7671c018)
34. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-c797dd8bfa43485d9c448f4cbaf7ccad)
35. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-85f2c6ebe27a4756b1361b1d123e3cf6)
36. [LONZA — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-8acb141ecc88461884952987e2eb9584)
37. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-05a9cda6bb804e82985f43a32ba4faa9)
38. [LONZA — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P-9cce667b6b0647ec9bf793959f8969dc)
39. [LONZA — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-f0b35cb1e1184af0a385d6938b4d3986)
40. [LONZA — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-b144f07b71cc4bdabd2f0057e4264899)
41. [LONZA — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-bfa865693eb64f40b03b2a1084c9683c)
42. [LONZA — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-dea544d3f3c44b71bb71038890915c08)
43. [LONZA — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-b918d1074fda4b34b84942fcf0745486)
44. [LONZA — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-70c1b0fa9842473d9b1bcb1513a83f3f)
45. [LONZA — Full financial report (2024 Y), p37](https://app.finbar.com/go?id=T-59d3f65f25ef4f58812b5bf3bd71e66c)
46. [LONZA — Presentation (2024 Y), p2](https://app.finbar.com/go?id=P-66df0a0a974f4238a4520e8fc8ff6a56)
47. [LONZA — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-1c9d6fc417324d46b42e7d9716922f65)
48. [www.lonza.com](https://www.lonza.com/about-us/our-locations)
49. [LONZA — Full financial report (2024 Y), p38](https://app.finbar.com/go?id=P-4ae6ade60bf8405197e319c8a35f369c)
50. [LONZA — Full financial report (2024 Y), p38](https://app.finbar.com/go?id=T-831b8bfd4c2f4934b95f0db502057557)
51. [LONZA — Full financial report (2024 Y), p14](https://app.finbar.com/go?id=P-48bf834b4b6f42c98ab36aa647984c8f)
52. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-d44eff9c490e4661b484a5ca2c0f88fe)
53. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-9a1ed28a20964acb9de95e76f67e636f)
54. [LONZA — Full financial report (2024 Y), p37](https://app.finbar.com/go?id=P-18cc4f170b7b4138a76a964987cbf37f)
55. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-0ac689f122aa4b2cb8029e04e122f3f5)
56. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-114828a44837411d8728946e0759a4cb)
57. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-468e4cb3967b4fa196b8eaa10e7fe053)
58. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-e35357d2ad554497998a8f1360791294)
59. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-bf80e7d54e8440bd8e0c3da38b5db0c4)
60. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-18a27f20885d44d3b3be6e0e8d44316c)
61. [LONZA — Full financial report (2024 Y), p36](https://app.finbar.com/go?id=P-cef56a8e07d04575b11f1f854b32976d)
62. [www.lonza.com](https://www.lonza.com/about-us/our-history)
63. [LONZA — Full financial report (2022 Y), p7](https://app.finbar.com/go?id=P-75c44695b6c24a5a91beb3c26eea5b93)
64. [LONZA — Full financial report (2022 Y), p8](https://app.finbar.com/go?id=P-8150cce485c84782ad8d6a799e5865a5)
65. [www.lonza.com](https://www.lonza.com/news/2017-07-06-05-00)
66. [www.lonza.com](https://www.lonza.com/news/2019-03-01-06-00)
67. [www.lonza.com](https://www.lonza.com/news/2021-07-02-07-00)
68. [www.lonza.com](https://www.lonza.com/news/2023-06-01-07-00)
69. [LONZA — Full financial report (2024 Y), p4](https://app.finbar.com/go?id=P-54edf26abc7a4aafb4c6e286b60843e0)
70. [LONZA — Full financial report (2024 Y), p4](https://app.finbar.com/go?id=P-0c136e2126b34597a4e02245b2a9572e)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.